Gastrointestinal and Cardiovascular Risks of Nonsteroidal Anti-inflammatory Drugs

American Journal of Medicine

Volumn 121, Issue 6, 2008, Pages 464-474

  Jones, Roger ^a   Rubin, Greg ^b   Berenbaum, Francis ^c   Scheiman, James ^d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SUNDERLAND   (United Kingdom)

^c SORBONNE UNIVERSITÉ   (France)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cardiovascular symptoms; Gastrointestinal symptoms; Gastroprotection; Morbidity; Mortality; Nonsteriodal anti inflammatory drugs; Risks

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; BISMUTH CITRATE; CELECOXIB; CIMETIDINE; CLARITHROMYCIN; CYCLOOXYGENASE 2; DICLOFENAC; ETORICOXIB; FAMOTIDINE; GASTROINTESTINAL AGENT; IBUPROFEN; LANSOPRAZOLE; LUMIRACOXIB; METRONIDAZOLE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PARACETAMOL; PARECOXIB; PLACEBO; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB; TETRACYCLINE; VALDECOXIB;

ADENOMATOUS POLYP; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; CLINICAL TRIAL; COLORECTAL CANCER; DIGESTIVE SYSTEM HEMORRHAGE; DIGESTIVE SYSTEM PERFORATION; DRUG MECHANISM; DRUG USE; DRUG WITHDRAWAL; DUODENUM ULCER; DYSPEPSIA; ERADICATION THERAPY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; HEART INFARCTION; HEARTBURN; HELICOBACTER PYLORI; HUMAN; LIVER TOXICITY; MONOTHERAPY; NOMENCLATURE; NONHUMAN; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; STOMACH ULCER; STROKE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR SYSTEM; CYCLOOXYGENASE 2 INHIBITORS; ENDOSCOPY, GASTROINTESTINAL; GASTROINTESTINAL TRACT; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MISOPROSTOL; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTON PUMP INHIBITORS; RISK ASSESSMENT;

EID: 43749091527     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.01.045     Document Type: Review

References (98)

1. Walt R., Katschinski B., Logan R., et al. Rising frequency of ulcer perforation in elderly people in the United Kingdom. Lancet 1 (1986) 489-492
2. Kean W.F., and Buchanan W.W. The use of NSAIDs in rheumatic disorders 2005: a global perspective. Inflammopharmacology 13 (2005) 343-370
3. Wolfe M.M., Lichtenstein D.R., and Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 340 (1999) 1888-1899
4. Micklewright R., Lane S., Linley W., and McQuade C. NSAIDs, gastroprotection and cyclo-oxygenase II selective inhibitors. Aliment Pharmacol Ther 17 (2003) 321-332
5. Welage L.S., and Berardi R.R. Evaluation of omeprazole, lansoprazole, pantoprazole and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash) 40 (2000) 52-62
6. Aares J.J., and Outt P.E. Gastroprotective agents for the prevention of NSAID-induced gastropathy. Curr Pharm Des 4 (1998) 17-36
7. Fries J.F. Selective cyclooxygenase inhibition: promise for future NSAID therapy?. Scand J Rheumatol Suppl 102 (1996) 23-28
8. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 (2000) 1520-1528
9. Josefson D. FDA warns Merck over its promotion of rofecoxib. BMJ 233 (2001) 767
10. Dieppe P.A., Ebrahim S., Martin R.M., and Juni P. Lessons from the withdrawal of rofecoxib. BMJ 329 (2004) 867-868
11. Hippisley-Cox J., Coupland C., and Logan R. Risk of adverse gastrointestinal outcomes in patients takingt cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 331 (2005) 1310-1316
12. Sheehan K.M., Sheahan K., O'Donoghue D.P., et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 282 (1999) 1254-1257
13. Kearney P.M., Baigent C., Godwin J., et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis?. Meta-analysis of randomized trials. BMJ 332 (2006) 1302-1308
14. Nussmeier N.A., Whelton A.A., Brown M.T., et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352 (2005) 1081-1091
15. Ott E., Nussmeier N.A., Duke P.C., et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 125 (2003) 1481-1492
16. Solomon D.H., Avorn J., Sturmer T., et al. Cardiovascular outcomes in new users of coxibs and nonsteroidal anti-inflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum 54 5 (2006) 1378-1389
17. Willoughby D.A., Moore A.R., and Colville-Nash P.R. COX-1, COX-2 and COX-3 and the future treatment of chronic inflammatory disease. Lancet 355 (2000) 646-648
18. Schwab J.M., Schluesener H.J., and Laufer S. COX-3: just another COX or the solitary elusive target of paracetamol?. Lancet 361 (2003) 981-982
19. Schoen R.T., and Vender R.J. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med 86 (1989) 449-458
20. Whittle B.J.R. Mechanisms underlying gastric mucosal damage induced by indomethacin and bile salts, and the actions of prostaglandins. Br J Pharmacol 60 (1977) 455-460
21. Wolfe M.M., and Sull A.H. The physiology of gastric acid secretion. N Engl J Med 319 (1988) 1307-1315
22. Graham D.Y., and Smith J.L. Aspirin and the stomach. Ann Intern Med 104 (1986) 390-398
23. Konturek S.J., Kwiecien N., Obtulowicz W., et al. Double blind controlled study on the effect of sucralfate on gastric prostaglandin formation and microbleeding in normal and aspirin treated man. Gut 27 (1986) 1450-1456
24. Berkowitz J.M., Rogenes P.R., Sharp J.T., and Warner C.W. Ranitidine protects against gastroduodenal mucosal damage associated with chronic aspirin therapy. Arch Intern Med 147 (1987) 2137-2139
25. Larkai E.N., Smith J.L., Lidsky M.D., and Graham D.Y. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic steroidal anti-inflammatory drug use. Am J Gastroenterol 82 (1987) 1153-1158
26. Singh G., Ramey D.R., Morfeld D., et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: a prospective observational cohort study. Arch Intern Med 156 (1996) 1530-1536
27. Armstrong C.P., and Blower A.L. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 28 (1987) 527-532
28. Silverstein F.E., Graham D.Y., Senior J.R., et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 123 (1995) 241-249
29. Laine L., Harper S., Simon T., et al. A randomized trial comparing the effect of rofecoxib, a COX-2-specific inhibitor, to ibuprofen on the gastroduodenal mucosa of osteoarthritis patients. Gastroenterology 117 (1999) 776-783
30. Hawkey C., Laine L., Simon T., et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. A randomized, double-blind, placebo-controlled trial. Arthritis Rheum 43 (2000) 370-377
31. Simon L.S., Weaver A.L., Graham D.Y., et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial. JAMA 282 (1999) 1921-1928
32. Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am 6 (1996) 489-504
33. Tseng C., and Wolfe M. Non steroidal anti-inflammatory drugs. Med Clin North Am 84 (2000) 1329-1344
34. Silverstein F., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteoridal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 284 (2000) 1247-1255
35. Lazzaroni M., and Bianchi Porro G. Gastrointestinal side-effects of traditional non-steroidal anit-inflammatory drugs and new formulations. Aliment Pharmacol Ther 20 Suppl 2 (2004) 48-58
36. Singh G., and Triadafilopoulus G. Epidemiology of NSAID-induced GI complications. J Rheumatol 26 Suppl 26 (1999) 18-24
37. Smalley W.E., Ray W.A., Daugherty J.R., and Griffin M.R. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 141 (1995) 539-545
38. Serrano P., Lanas A., Arroyo M.T., et al. Risk stratification of upper gastrointestinal bleeding in cardiovascular patients on low-dose aspirin. A cohort study. Gastroenterology 118 (2000) A862
39. Gabriel S.E., Jaakkimainen L., and Bombardier C. Risk for serious gastrointestinal complications related to the use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 115 (1991) 787-796
40. Lanza L.L., Walker A.M., Bortnichak E.A., and Dreyer N.A. Peptic ulcer and gastrointestinal hemorrhage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years. A large health maintenance organization cohort study. Arch Intern Med 155 (1995) 1371-1377
41. Garcia Rodriguez L.A., and Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 343 (1994) 769-772
42. Talley N.J., Evans J.M., Fleming K.C., et al. Nonsteroidal anti-inflammatory drugs and dyspepsia in the elderly. Dig Dis Sci 40 (1995) 1345-1350
43. Larkai E.N., Smith J.L., Lidsky M.D., et al. Dyspepsia in NSAID users: the size of the problem. J Clin Gastroenterol 11 (1989) 158-162
44. Chan F.K.L., Sung J.J.Y., Chung S.C.S., et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 350 (1997) 975-979
45. Hawkey C.J., Tulassay Z., Szczepanski L., et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Lancet 352 (1998) 1016-1021
46. Chan F.K., Sung J.J., Suen R., et al. Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers?. A prospective randomized study. Aliment Pharmacol Ther 12 (1998) 1201-1205
47. Chan F.K., Sung J.J., Suen B.Y., et al. Prospective randomized trial of H.pylori eradication versus maintenance omeprazole to prevent recurrent upper gastrointestinal hemorrhage in high-risk aspirin and non-aspirin NSAID users. Gastroenterology 118 (2000) A194
48. Huang J.-Q., Sridhar S., and Hunt R.H. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 359 (2002) 14-22
49. Weil J., Langman M.J.S., Wainwright P., et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 46 (2000) 27-31
50. Rockall T.A., Logan R.F.A., Devlin H.B., and Northfield T.C. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 38 (1996) 316-321
51. Piper J.M., Ray W.A., Daugherty J.R., and Griffin M.R. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 114 (1991) 735-740
52. Shorr R.I., Ray W.A., Daugherty J.R., and Griffin M.R. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhage peptic ulcer disease. Arch Intern Med 153 (1993) 1665-1670
53. Hansen J.M., Hallas J., Lauritsen J.M., and Bytzer P. Non-steroidal anti-inflammatory drugs and complications: a risk factor analysis for clinical decision-making. Scand J Gastroenterol 31 (1996) 126-130
54. Gutthann S.P., Garcia Rodriguez L.A., and Raiford D.S. Individual nonsteroidal anti-inflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 8 (1997) 18-24
55. Hernandez-Diaz S., and Garcia Rodriquez L.A. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation. Arch Intern Med 160 (2000) 2093-2099
56. Pope J.E., Anderson J.J., and Felson D.T. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 153 (1993) 477-484
57. Johnson A.G., Nguyen T.V., and Day R.O. Do nonsteroidal anti-inflammatory drugs affect blood pressure: a meta-analysis. Ann Intern Med 121 (1994) 289-300
58. Salpeter S.R., Gregor P., Ormiston T.M., et al. Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. Am J Med 119 (2006) 552-559
59. Bresalier R.S., Sandler R.S., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
60. Juni P., Nartey L., Reichenbach S., et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364 (2004) 2021-2029
61. McGettigan P., and Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase. JAMA 296 (2006) 1633-1644
62. Hernandez-Diaz S., Varas-Lorenzo C., and Garcia Rodriguez L.A. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 98 (2006) 266-274
63. Solomon S.D., McMurray J.J., Pfeffer M.A., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
64. Moskowitz R.W., Sunshine A., Brugger A., et al. American pain society pain questionnaire and other pain measures in the assessment of osteoarthritis pain: a pooled analysis of three celecoxib pivotal studies. Am J Ther 10 (2003) 12-20
65. Caldwell B., Aldington S., Weatherall M., et al. Risk of cardioivascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 99 (2006) 132-140
66. Farkouh M.E., Kirshner H., and Harrington R.A. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomized controlled trial. Lancet 364 (2004) 675-684
67. Sheldon E., Beaulieu A., Paster Z., et al. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo. Clin Ther 27 (2005) 64-77
68. Lehmann R., Brzosko M., Kopsa P., et al. Efficacy and tolerability of lumiracoxib 100mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib. Curr Med Res Opin 21 (2005) 517-526
69. Hawkey C.J., Gitton X., Hoexter G., et al. Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis. Clin Gastroenterol Hepatol 4 (2006) 57-66
70. Aldington S., Shirtcliffe P., Weatherall M., and Beasley R. Increased risk of cardiovascular events with parecoxib/valdecoxib: a systematic review and meta-analysis. N Z Med J 118 1226 (2005) U1755
71. Aldington S., Shirtcliffe P., Weatherall M., and Beasley R. Systematic review and meta-analysis of the risk of major cardiovascular events with etoricoxib therapy. N Z Med J 118 1223 (2005) U1684
72. FDA Advisory Committee Background Information. Cardiovascular-Renal Safety Review (VIGOR). Merck Research Laboratories, Rofecoxib NDA 21-042; 57-59. http://www.fda.gov/ohrms/dockets/ac/cder01.htm#Arthritis
73. Whelton A., White W.B., Bello A.E., Puma J.A., Fort J.G., and SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 90 (2002) 959-963
74. Sowers J.R., White W.B., Pitt B., et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis and type 2 diabetes mellitus. Arch Intern Med 165 (2005) 161-168
75. Grosser T., Fries S., and FitzGerald G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116 (2006) 4-15
76. Fries S., Grosser T., Price T.S., et al. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology 130 (2006) 55-64
77. Wallace J.L., McKnight W., Reuter B.K., and Vergnolle N. NSAIDs-induced gastric damage in rats: requirement for inhibition of both Cyclooxygenase 1 and 2. Gastroenterology 119 (2000) 706-714
78. Rostom A., Dube C., Wells G., et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 4 (2002) CD002296
79. Hooper L., Brown T.J., Elliott R., et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: a systematic review. BMJ 329 (2004) 948
80. Leandro G., Pilotto A., Franceschi M., et al. Prevention of acute NSAID-related gastroduodenal damage: a meta-analysis of controlled clinical trials. Dig Dis Sci 46 (2001) 1924-1936
81. Hawkey C., Talley N.J., Yeomans N.D., et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal, anti-inflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol 100 (2005) 1028-1036
82. Graham D.Y., Agrawal N.M., Campbell D.R., et al. Ulcer prevention in long term users of non-steroidal anti-inflammatory drugs: results of a double-blind randomised, multicenter, active and placebo-controlled study of misoprostol versus lansoprazole. Arch Intern Med 162 (2002) 169-175
83. Chan F.K., To K.F., Wu J.C., et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 359 (2002) 9-13
84. Chan F.K., Chung S., Suen B.Y., et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspiring or naproxen. N Engl J Med 344 (2001) 967-973
85. Schnitzer T.J., Burmester G.R., Mysler E., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364 (2004) 665-674
86. Chan F.K., Hung L.C., Suen B.Y., et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347 (2002) 2104-2110
87. Lai K.C., Chu K.M., Hui W.M., et al. Celecoxib compared to lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 118 (2005) 1271-1278
88. Hur C., Chan A.T., Tramontano A.C., and Gazelle G.S. Coxibs versus combination NSAID and proton pump inhibitor therapy for chronic pain: an exploration of the risks, benefits and costs. Ann Pharmacother 40 (2006) 1052-1063
89. Elliott R.A., Hooper L., Payne K., et al. Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population?. Rheumatology 45 (2006) 606-613
90. Woo WW, Man SY, Lam PK, Rainer TH. Randomized double-blind trail comparing oral pharacetamol and oral nonsteroidal anti-inflammatory drugs for treating pain after musculoskeletal injury. Ann Emerg Med. 1005;46:352-361.
91. Superuio-Cabuslay E., Ward M.M., and Lorig K.R. Patient education interventions in osteroarthritis and rheumatoid arthritis: a meta-analytic comparison with nonsteroidal anti-inflammatory drug treatment. Arthritis Care Res 9 (1996) 292-301
92. Nielson W.R., and Weir R. Biopsychosocial approaches to the treatment of chronic pain. Clin J Pain 17 4 Suppl (2001) S114-S127
93. Deyle G.D., Allison S.C., Matekel R.L., et al. Physical therapy treatment effectiveness for osteoarthritis of the knee: a randomized comparison of supervised clinical exercise and manual therapy procedures versus a home exercise program. Phys Ther 85 (2005) 1301-1317
94. Bennell K., and Hinman R. Exercise as a treatment for osteoarthritis. Curr Opin Rheumatol 17 (2005) 634-640
95. Malfertheiner P., Megraud F., O'Morain C., et al. Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 16 (2002) 167-180
96. Scheiman J.M., and Cryer B. Panel discussion: treatment approaches to control gastrointestinal risk and balance cardiovascular risks and benefits: proposals and recommendations. Aliment Pharmacol Ther Symp Ser 1 (2005) 26-32
97. Pearson T.A., Blair S.N., Daniels S.R., et al., American Heart Association Science Advisory and Coordinating Committee. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 106 (2002) 388-391
98. Scheiman J.M., and Fendrick A.M. Summing the risk of NSAID therapy. Lancet 369 (2007) 1580-1581